Firstly, as a human being I hope it does.
Secondly, it will be a while before/if this is proven. A lot can happen in that time. I don't know what percentage of patients would be able to discontinue without relapse. Has NVS indicated any estimates?
Peter has said that pretty much anything Tasigna and Sprycel can do, Ponatinib can do better. Would it not be logical to reason that the most potent and powerful TKI would cause this result as well, if not even more. If that is the case, perhaps an opportunity for Ponatinib to become THE main player in CML, with a percentage of patients being able to discontinue and the rest remaining mutation free.
